Compare Abeona Therapeutics Inc (ABEO) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ING Groep NV — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while ING Groep NV trades at $31.83 (market cap $92.35B). The key difference: ING Groep NV is far larger — about 247.4× Abeona Therapeutics Inc's market cap, and ING Groep NV pays a 3.93% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | ING | |
|---|---|---|
Market Cap | $373.32M | $92.35B |
Sector | Health | Financials |
52-Week High | $7.23 | $32.96 |
52-Week Low | $4.17 | $22.45 |
Enterprise Value | $228.22M | — |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ING trades at $32.24, up 0.44% today, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats and a 27.84% net income margin. Recent news highlights strategic moves like a global subscription banking model and board appointments, reinforcing growth initiatives. Analyst consensus is strongly positive with 62.5% buy ratings.
The outlook remains favorable due to solid fundamentals and bullish sentiment, though risks include volatile cash flows and macroeconomic pressures. Upside potential is supported by a DCF intrinsic value of $34, suggesting modest appreciation from current levels. Investors should weigh strong profitability against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
